ACIU Net Debt vs Total Assets Analysis

ACIU Stock  USD 3.38  0.09  2.74%   
AC Immune financial indicator trend analysis is way more than just evaluating AC Immune prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AC Immune is a good investment. Please check the relationship between AC Immune Net Debt and its Total Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.

Net Debt vs Total Assets

Net Debt vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AC Immune Net Debt account and Total Assets. At this time, the significance of the direction appears to have pay attention.
The correlation between AC Immune's Net Debt and Total Assets is -0.8. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Total Assets in the same time period over historical financial statements of AC Immune, assuming nothing else is changed. The correlation between historical values of AC Immune's Net Debt and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of AC Immune are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Net Debt i.e., AC Immune's Net Debt and Total Assets go up and down completely randomly.

Correlation Coefficient

-0.8
Relationship DirectionNegative 
Relationship StrengthSignificant

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Total Assets

Total assets refers to the total amount of AC Immune assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in AC Immune books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from AC Immune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AC Immune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.At this time, AC Immune's Tax Provision is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 498.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 8.3 M in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses79.0M74.8M13.8M13.1M
Cost Of Revenue62.3M60.3M54.6M45.8M

AC Immune fundamental ratios Correlations

0.910.91.00.940.98-0.470.060.810.83-0.040.750.950.980.820.810.870.54-0.80.50.520.970.880.690.930.91
0.910.960.90.860.83-0.6-0.030.590.89-0.060.740.980.830.860.870.920.36-0.580.650.340.820.890.770.940.91
0.90.960.890.830.84-0.51-0.040.620.82-0.170.680.980.840.780.830.870.51-0.60.570.490.840.820.690.920.84
1.00.90.890.940.98-0.460.070.820.83-0.040.740.940.980.810.810.860.54-0.810.490.530.970.880.680.920.9
0.940.860.830.940.96-0.30.080.850.70.020.630.890.960.660.70.750.49-0.840.310.470.960.750.520.90.8
0.980.830.840.980.96-0.350.090.90.75-0.040.690.91.00.720.720.780.59-0.890.340.580.990.810.570.90.85
-0.47-0.6-0.51-0.46-0.3-0.350.1-0.06-0.76-0.34-0.86-0.55-0.31-0.84-0.86-0.750.120.01-0.950.07-0.3-0.75-0.89-0.59-0.66
0.06-0.03-0.040.070.080.090.10.24-0.10.0-0.16-0.020.080.03-0.13-0.12-0.41-0.26-0.08-0.470.090.04-0.26-0.05-0.05
0.810.590.620.820.850.9-0.060.240.45-0.120.480.680.90.440.430.460.51-0.990.010.50.910.570.220.680.63
0.830.890.820.830.70.75-0.76-0.10.450.090.830.870.720.950.910.960.28-0.440.720.290.70.970.930.890.96
-0.04-0.06-0.17-0.040.02-0.04-0.340.0-0.120.090.29-0.05-0.070.150.180.04-0.170.140.27-0.1-0.120.090.170.050.03
0.750.740.680.740.630.69-0.86-0.160.480.830.290.760.660.880.940.840.23-0.440.780.280.650.880.880.820.83
0.950.980.980.940.890.9-0.55-0.020.680.87-0.050.760.890.850.870.920.49-0.670.580.480.890.890.750.980.9
0.980.830.840.980.961.0-0.310.080.90.72-0.070.660.890.680.70.760.6-0.90.310.591.00.780.540.880.83
0.820.860.780.810.660.72-0.840.030.440.950.150.880.850.680.930.950.19-0.430.820.20.660.980.930.860.93
0.810.870.830.810.70.72-0.86-0.130.430.910.180.940.870.70.930.950.26-0.390.850.290.690.920.940.90.86
0.870.920.870.860.750.78-0.75-0.120.460.960.040.840.920.760.950.950.35-0.440.760.340.740.950.930.930.93
0.540.360.510.540.490.590.12-0.410.510.28-0.170.230.490.60.190.260.35-0.51-0.060.990.590.270.210.450.35
-0.8-0.58-0.6-0.81-0.84-0.890.01-0.26-0.99-0.440.14-0.44-0.67-0.9-0.43-0.39-0.44-0.510.03-0.5-0.9-0.56-0.2-0.67-0.63
0.50.650.570.490.310.34-0.95-0.080.010.720.270.780.580.310.820.850.76-0.060.03-0.040.310.710.860.580.61
0.520.340.490.530.470.580.07-0.470.50.29-0.10.280.480.590.20.290.340.99-0.5-0.040.580.280.250.460.35
0.970.820.840.970.960.99-0.30.090.910.7-0.120.650.891.00.660.690.740.59-0.90.310.580.760.520.860.81
0.880.890.820.880.750.81-0.750.040.570.970.090.880.890.780.980.920.950.27-0.560.710.280.760.890.920.97
0.690.770.690.680.520.57-0.89-0.260.220.930.170.880.750.540.930.940.930.21-0.20.860.250.520.890.790.84
0.930.940.920.920.90.9-0.59-0.050.680.890.050.820.980.880.860.90.930.45-0.670.580.460.860.920.790.91
0.910.910.840.90.80.85-0.66-0.050.630.960.030.830.90.830.930.860.930.35-0.630.610.350.810.970.840.91
Click cells to compare fundamentals

AC Immune Account Relationship Matchups

AC Immune fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets299.3M238.7M261.4M185.9M182.8M177.6M
Other Current Liab11.8M11.1M16.7M9.4M11.1M9.5M
Total Current Liabilities17.5M14.0M20.0M11.5M13.6M12.8M
Total Stockholder Equity272.4M215.5M232.0M169.0M160.6M158.5M
Other Liab7.5M7.5M7.1M3.2M3.7M5.0M
Net Tangible Assets272.4M215.5M181.6M118.6M136.4M145.5M
Retained Earnings(75.5M)(132.9M)(200.9M)(264.0M)(316.2M)(300.4M)
Accounts Payable142K2.2M2.0M929K1.7M1.4M
Cash193.6M160.9M82.2M31.6M78.5M107.1M
Net Receivables1.4M1.6M975K800K15.0M15.8M
Other Current Assets4.2M4.0M3.0M4.7M6.4M6.8M
Total Liab26.8M23.3M29.5M16.9M22.2M19.1M
Total Current Assets292.8M231.8M202.6M128.1M125.2M157.9M
Common Stock1.4M1.5M1.8M1.8M2.1M1.5M
Property Plant Equipment6.2M6.6M8.0M7.1M8.1M8.5M
Property Plant And Equipment Net6.2M6.6M8.0M7.1M6.9M4.7M
Current Deferred Revenue4.5M306K717K587K138K131.1K
Net Debt(190.7M)(158.7M)(79.3M)(28.8M)(75.0M)(78.7M)
Non Current Assets Total6.5M7.0M58.8M57.8M57.7M60.5M
Non Currrent Assets Other6.5M334K363K361K415.2K394.4K
Cash And Short Term Investments288.6M225.9M198.2M122.6M103.0M162.9M
Common Stock Total Equity1.1M1.4M1.4M1.5M1.8M1.3M
Common Stock Shares Outstanding71.1M71.9M75.0M83.6M84.7M73.3M
Short Term Investments95M65M116M91M24.6M46.4M
Liabilities And Stockholders Equity299.3M238.7M261.4M185.9M182.8M193.9M
Non Current Liabilities Total9.3M9.2M9.4M5.5M8.6M6.9M
Capital Lease Obligations2.3M2.2M2.9M2.8M3.5M3.7M
Inventory(1.4M)(1.9M)(1.4M)1.0(622K)(590.9K)
Other Stockholder Equity346.5M346.8M431.1M431.2M474.8M300.1M
Property Plant And Equipment Gross6.2M6.6M15.6M7.1M17.9M18.8M
Accumulated Other Comprehensive Income179.4M(3.5M)0.010K(51K)(48.5K)
Short Term Debt1.1M443K570K548K672K402.5K
Short Long Term Debt Total2.9M2.2M2.9M2.8M3.5M2.1M
Net Invested Capital273.1M215.5M232.0M169.0M160.6M211.4M
Net Working Capital275.3M217.7M182.6M116.6M111.6M137.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.